Clinical Trials Logo

Clinical Trial Summary

Asthma is a heterogeneous disease characterized by chronic airway inflammation characterized by time-varying respiratory symptoms such as wheezing, shortness of breath, chest tightness and cough, with limitation of expiratory airflow. These variations are often triggered by exercise, exposure to allergens or an irritation, weather changes or viral respiratory diseases (Karakış, 2018). Increased respiratory distress decreases the patient's activity, decreases the condition and makes the individual dependent in daily life. In the studies conducted in asthma patients, the cases stated that they perceived their illness as an obstacle against physical activity and thus they were pushed to immobility (Kırtay & Oğuz, 2011). In the literature, no study on the variable of kinesiophobia in asthma was found. The aim of this study was to investigate the relationship between kinesiophobia and physical activity level and quality of life in asthma patients.


Clinical Trial Description

Asthma is a chronic inflammatory disease characterized by increased airway sensitivity to various stimuli and reversible airway obstruction (Soyuer et al., 2013). Bronchial hypersensitivity associated with chronic airway inflammation causes wheezing, dyspnea, chest tightness, and cough attacks, especially at midnight or morning. These attacks are associated with varying degrees of airway obstruction and usually improve with treatment or spontaneously (Arslan, 2011). Three mechanisms are responsible for the pathogenesis of asthma. These include reversible airway obstruction, airway inflammation, and increased airway sensitivity (Soyuer et al., 2013). Although it is known that genetic and environmental factors play a role in asthma formation, etiopathogenesis has not been fully explained (Arslan, 2011). Approximately 300 million people worldwide suffer from asthma and this prevalence increases by 50% every ten years. Hospitalization is frequently seen in patients with asthma (Autumn, 2015). It is estimated that approximately 250,000 people die annually due to asthma. No relationship was found between prevalence and mortality (Autumn, 2015). Asthmatic patients have intermittent symptoms such as wheezing, dyspnea, chest tightness, and dry cough. Stimulants such as allergens, air pollution, gastroesophageal reflux, stress and exercise cause these symptoms. 90% of untreated asthmatics develop asthma symptoms during exercise (Dursun et al., 2013). Airway obstruction due to exercise occurs in 40-90% of asthmatics, decreases the ability to exercise and patients prefer a more sedentary lifestyle. Patients with asthma have low physical activity levels because they avoid exercising due to anxiety and depression, inactivity, fatigue, dyspnea (Autumn, 2015). The ability to perform activities and the ability to perform daily living activities are components of quality of life. In many studies, it has been found that quality of life is affected in individuals with chronic lung disease. Quality of life can be assessed with many disease-specific questionnaires. Asthma patients experience problems in many areas in terms of quality of life, including day and night disease symptoms, impaired daily living activities, and reduced quality of life. Asthma is associated with decreased quality of life and morbidity. Asthma symptoms reduce performance at school and at work; affects learning and reduces quality of life. It is stated that asthma has a negative effect on quality of life, physical, physiological and social function (Autumn, 2015).

Airway obstruction due to exercise decreases physical activity in asthmatic patients. This may give rise to fear of movement over time. Avoidance of movement is called kinesiophobia. Kinesiophobia is a condition that occurs when patients want to perform their previous functions, especially in chronic painful disease processes.

Kinesiophobia is an avoidance phenomenon within the cognitive behavioral avoidance model and patients may limit their activity in daily life in case of symptoms of deterioration or the occurrence of symptoms. This may result in emotional problems and life dissatisfaction in later periods (Yumin et al., 2017). Kinesiophobia has been the subject of study in cardiopulmonary cases, but there is no research on kinesiophobia in asthma. In this study, the effect of kinesiophobia on physical activity level and quality of life in asthma will be investigated. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04181905
Study type Observational
Source Marmara University
Contact SEDA KARACA
Phone 05077743857
Email aisa.sed@gmail.com
Status Recruiting
Phase
Start date April 21, 2019
Completion date February 2021

See also
  Status Clinical Trial Phase
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device